138 related articles for article (PubMed ID: 9457836)
1. A survey of current clinical practice of permanent prostate brachytherapy in the United States.
Prestidge BR; Prete JJ; Buchholz TA; Friedland JL; Stock RG; Grimm PD; Bice WS
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):461-5. PubMed ID: 9457836
[TBL] [Abstract][Full Text] [Related]
2. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
3. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States.
Prete JJ; Prestidge BR; Bice WS; Friedland JL; Stock RG; Grimm PD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):1001-5. PubMed ID: 9531387
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
[TBL] [Abstract][Full Text] [Related]
5. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.
Lee WR; deGuzman AF; Bare RL; Marshall MG; McCullough DL
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):83-8. PubMed ID: 10656377
[TBL] [Abstract][Full Text] [Related]
6. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
7. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
8. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update.
Buyyounouski MK; Davis BJ; Prestidge BR; Shanahan TG; Stock RG; Grimm PD; Demanes DJ; Zaider M; Horwitz EM
Brachytherapy; 2012; 11(4):299-305. PubMed ID: 22330104
[TBL] [Abstract][Full Text] [Related]
9. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
Potters L; Torre T; Ashley R; Leibel S
J Clin Oncol; 2000 Mar; 18(6):1187-92. PubMed ID: 10715287
[TBL] [Abstract][Full Text] [Related]
10. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
11. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
Nag S; Beyer D; Friedland J; Grimm P; Nath R
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):789-99. PubMed ID: 10386635
[TBL] [Abstract][Full Text] [Related]
12. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for antibiotic prophylaxis in transperineal interstitial permanent prostate brachytherapy?
Dicker AP; Figura AT; Waterman FM; Valicenti RK; Strup SE; Gomella LG
Tech Urol; 2000 Jun; 6(2):104-8. PubMed ID: 10798809
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy.
Schwartz DJ; Schild SE; Wong WW; Vora SA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):60-3. PubMed ID: 15629594
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review of prostate cancer brachytherapy: defining an optimal technique.
Vicini FA; Kini VR; Edmundson G; Gustafson GS; Stromberg J; Martinez A
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):483-91. PubMed ID: 10348275
[TBL] [Abstract][Full Text] [Related]
16. Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: patterns of care study.
Eifel PJ; Moughan J; Owen J; Katz A; Mahon I; Hanks GE
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):351-8. PubMed ID: 10030261
[TBL] [Abstract][Full Text] [Related]
17. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric study of Cs-131, I-125, and Pd-103 seeds for permanent prostate brachytherapy.
Yang R; Wang J; Zhang H
Cancer Biother Radiopharm; 2009 Dec; 24(6):701-5. PubMed ID: 20025550
[TBL] [Abstract][Full Text] [Related]
19. Skin surface brachytherapy: A survey of contemporary practice patterns.
Likhacheva AO; Devlin PM; Shirvani SM; Barker CA; Beron P; Bhatnagar A; Doggett SW; Hochman L; Hsu C; Kasper M; Keisch M; Mutyala S; Prestidge B; Rodriguez Villalba S; Shukla V; Sundararaman S; Kamrava M
Brachytherapy; 2017; 16(1):223-229. PubMed ID: 27908679
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
Prestidge BR; Hoak DC; Grimm PD; Ragde H; Cavanagh W; Blasko JC
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):31-9. PubMed ID: 9054874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
